Astex will also present the first disclosure of the full chemical structure of AT9283, its multi-targeted kinase inhibitor. AT9283 is currently being tested in multiple Phase I and Phase I/IIa human clinical trials for the treatment of a variety of solid tumours and haematological malignancies. Early evidence of clinical activity has been observed in patients treated with AT9283.
The Company will also present data on its selective JAK2 inhibitor programme, which is targeting the treatment of a number of myeloproliferative diseases. The selective JAK2 inhibitor programme is designed to complement the JAK2 inhibitory activity already observed in myelofibrosis patients treated with AT9283.
1European Organisation for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research
Contacts Jeremy Carmichael, PhD Director of Business Development
Astex Therapeutics Ltd 436 Cambridge Science Park Milton Road, Cambridge CB4 0QA, UK
Tel: +44(0)1223 226289 Fax: +44(0)1223 226201 j.carmichael@astex-therapeutics.com www.astex-therapeutics.com